Author

Hazel Hunt

Corcept Therapeutics (United States)ORCID 0000-0002-4316-1301Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell-cell communication· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Aakanksha VermaiD· 1 shared Adam G. SowalskyiD· 1 shared Alejandro A. SchäfferiD· 1 shared Alessandro GennaiD· 1 shared Andrew E. GreensteiniD· 1 shared Anson T. KuiD· 1 shared Ariel AfekiD· 1 shared Arunachalam SekariD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Aakanksha VermaORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologybioRxivPreprintJan 17, 2025

TMPRSS2-ERG confers resistance to antiandrogens: mechanism and therapeutic implications

Arunachalam Sekar, Rishita Chatterjee, Boobash Raj Selvadurai…·Yosef Yarden

This study shows that TMPRSS2-ERG fusion promotes resistance to antiandrogens by interacting with GR, suggesting combined GR and AR inhibition could benefit tERG-positive prostate cancer patients.

1 citation

humanbulk RNA-seq

𝕏 PostBluesky